共 50 条
Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: Design and rationale of the ROADMAP clinical trial
被引:25
|作者:
Rogers, Joseph G.
[1
]
Boyle, Andrew J.
[2
]
O'Connell, John B.
[3
]
Horstmanshof, Douglas A.
[4
]
Haas, Donald C.
[5
]
Slaughter, Mark S.
[6
]
Park, Soon J.
[7
]
Farrar, David J.
[3
]
Starling, Randall C.
[8
]
机构:
[1] Duke Univ, Div Cardiol, Durham, NC 27710 USA
[2] Cleveland Clin Florida, Weston, FL USA
[3] Thoratec Corp, Pleasanton, CA USA
[4] INTEGRIS Baptist Med Ctr, Oklahoma City, OK USA
[5] Abington Mem Hosp, Abington, PA USA
[6] Univ Louisville, Louisville, KY 40292 USA
[7] Univ Hosp Case Med Ctr, Cleveland, OH USA
[8] Cleveland Clin, Cleveland, OH USA
关键词:
INTERMACS ANNUAL-REPORT;
CONTINUOUS-FLOW;
CIRCULATORY SUPPORT;
TRANSPLANTATION;
SURVIVAL;
OUTCOMES;
REGISTRY;
THERAPY;
MODEL;
D O I:
10.1016/j.ahj.2014.11.004
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background Mechanical circulatory support is now a proven therapy for the treatment of patients with advanced heart failure and cardiogenic shock. The role for this therapy in patients with less severe heart failure is unknown. Objective The objective of this study is to examine the impact of mechanically assisted circulation using the HeartMate II left ventricular assist device in patients who meet current US Food and Drug Administration-defined criteria for treatment but are not yet receiving intravenous inotropic therapy. Methods This is a prospective, nonrandomized clinical trial of 200 patients treated with either optimal medical management or a mechanical circulatory support device. Clinical context This trial will be the first prospective clinical evaluation comparing outcomes of patients with advanced ambulatory heart failure treated with either ongoing medical therapy or a left ventricular assist device. It is anticipated to provide novel insights regarding relative outcomes with each treatment and an understanding of patient and provider acceptance of the ventricular assist device therapy. This trial will also provide information regarding the risk of events in "stable" patients with advanced heart failure and guidance for the optimal timing of left ventricular assist device therapy.
引用
收藏
页码:205 / +
页数:26
相关论文